Analysts Bullish on Healthpeak Properties’ Growth Trajectory

Market sentiment toward Healthpeak Properties, a leading healthcare real estate investment trust (REIT), is currently positive, with several financial institutions recently reaffirming their confidence in the stock. Research indicates significant potential upside, with consensus price targets suggesting gains of up to 30% from current trading levels.

The average price targets from various analyst compilations present an optimistic picture. Figures range between $20.30 and $22.19 per share. With the stock recently trading around $17.02, this implies a notable appreciation potential for investors. The stock's 52-week range has been between $16.63 and $21.83, with technical analysis identifying resistance levels in the $20.87 to $21.33 zone.

This optimism is rooted in the company's operational fundamentals. Healthpeak, which specializes in outpatient medical buildings, life science facilities, and senior housing, reported strong cash re-leasing spreads in its outpatient portfolio and an improving sentiment within its biopharma segment for the third quarter of 2025. These underlying business trends are key drivers supporting the favorable analyst outlook.

Consensus Ratings and Recent Research Updates

The analyst community has been active in its assessment. A summary from December 4th shows an average rating of "Moderate Buy" among twelve covering firms, supported by seven "Buy" and five "Hold" recommendations. The consensus price target from this group stands at $20.91.

Should investors sell immediately? Or is it worth buying Healthpeak Properties?

Further reports from December 5th reinforce this stance:
* One evaluation of ten analysts averages a "Buy" rating with a $20.30 target.
* Another, broader survey of twenty-two researchers points to an even higher average target of $22.19.

Among individual actions, Wells Fargo set a price objective of $19.00 on November 25th.

Upcoming Catalysts and Confirmed Guidance

Investors are now looking ahead to the next major milestone: the release of fourth-quarter and full-year 2025 results, expected in late January or early February. The company's management has previously confirmed its annual guidance, projecting adjusted funds from operations (FFO) per share in the range of $1.81 to $1.87. Furthermore, growth in adjusted net operating income (NOI) is forecasted to be between 3.0% and 4.0%. These figures will be closely scrutinized for confirmation of the company's strategic progress.